News

Published on 21 Mar 2023 on Benzinga via Yahoo Finance

Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks


Article preview image

The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk.FDA officials could decide within a few weeks and could change their mind, Wall Street Journal reported citing the people close to the matter.The deliberations come as some people especially vulnerable to infection have asked their doctors to give them a second round of the updated booster, even though the FDA hasn’t approved it.Some infectious-disease experts have called on federal health officials to permit another booster shot to safeguard people with comparatively weaker immune defenses better, as the U.K. and Canada have done.According to data from the CDC, people who get the shots are one-fourteenth as likely to die than unvaccinated people who didn’t get the updated shot.Yet less than 17% of the total population have taken a second booster, compared with 69% who got the primary series, according to the CDC. About 40% of people 65 years and older have received the updated, dual-target shot below earlier levels.In August, the FDA approved the bivalent COVID boosters targeting the BA.4 and BA.5 Omicron subvariants from Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA), along with the original strain.Photo by Johaehn from Pixabay

NYSE.PFE price evolution
NASDAQ.MRNA price evolution
NASDAQ.BNTX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
BioNTech stock target cut to $91 from $100 by Goldman Sachs By Investing.com

BioNTech stock target cut to $91 from $100 by Goldman Sachs

Investing.com 21 Mar 2024

BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials

BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer In...

Benzinga via Yahoo Finance 20 Mar 2024

BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool. BioNTech Se (NASDAQ: BNTX)Q4 2023 Earnings CallMar 20, 2024, 8:00 ...

Motley Fool via Yahoo Finance 20 Mar 2024

Why Moderna Shares Are Falling - Moderna (NASDAQ:MRNA)

Moderna Inc MRNA shares are trading lower by 2.7% to $102.25 during Wednesday’s session in possib...

Benzinga 20 Mar 2024

Why Is BioNTech Stock Trading Lower On Wednesday? - BioNTech (NASDAQ:BNTX)

Pfizer Inc’s PFE German partner, BioNTech SE BNTX, reported fourth-quarter 2023 EPS of fiscal yea...

Benzinga 20 Mar 2024

BioNTech stock slips after Q4 results (NASDAQ:BNTX)

BioNTech (BNTX) reports Q4 financials, with a ~65% drop in revenue due to declining demand for CO...

Seeking Alpha 20 Mar 2024

BioNTech Q4 earnings: COVID franchise to drive cash in 2024

BioNTech reported its financial results for the fourth quarter today. Here's what its CEO Ugur Sa...

Invezz 20 Mar 2024

BioNTech names new chief commercial officer ahead of launches

BioNTech names new chief commercial officer ahead of launches

Investing.com 20 Mar 2024

BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript

BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript March 20, 2024 BioNTech SE misses on e...

Insider Monkey via Yahoo Finance 20 Mar 2024

Will Weakness in BioNTech SE's (NASDAQ:BNTX) Stock Prove Temporary Given Strong Fundamentals?

With its stock down 7.5% over the past three months, it is easy to disregard BioNTech (NASDAQ:BNT...

Simply Wall St. via Yahoo Finance 12 Mar 2024